U.S. markets close in 6 hours 24 minutes
  • S&P 500

    4,280.48
    -24.72 (-0.57%)
     
  • Dow 30

    33,994.82
    -157.19 (-0.46%)
     
  • Nasdaq

    13,006.97
    -95.58 (-0.73%)
     
  • Russell 2000

    2,020.53
    -0.82 (-0.04%)
     
  • Crude Oil

    87.21
    +0.68 (+0.79%)
     
  • Gold

    1,787.20
    -2.50 (-0.14%)
     
  • Silver

    19.85
    -0.23 (-1.15%)
     
  • EUR/USD

    1.0164
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    2.8770
    +0.0530 (+1.88%)
     
  • GBP/USD

    1.2061
    -0.0034 (-0.28%)
     
  • USD/JPY

    135.2200
    +1.0050 (+0.75%)
     
  • BTC-USD

    23,636.54
    -344.86 (-1.44%)
     
  • CMC Crypto 200

    561.77
    -11.05 (-1.93%)
     
  • FTSE 100

    7,511.16
    -24.90 (-0.33%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights.

To access a live or recorded webcast of the call, please visit the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (United States) or (760) 298-5103 (international). The conference call passcode is 2177774.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com